Eli Lilly and Co said on Tuesday that its combo treatment, Cyramza, met the main...
FILE PHOTO: The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. REUTERS/Vincent Kessler
(Reuters) - Eli Lilly and Co said on Tuesday that its combo treatment, Cyramza, met the main goal in a late-stage study in patients with a form of lung cancer.
Lilly’s Cyramza in combination with Roche Holding’s erlotinib showed a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment.
Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur